Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financi...(nual Health Care Conference March 17-20 ...)

Massachusetts

-- Lehman Brothers Eleventh Annual Global Healthcare Conference,

March 18-20, 2008, Miami, Florida

-- 8th Annual Fortis Biotechnology Conference, April 3, 2008, London,

England

-- 2008 Morgan Stanley Global Healthcare Unplugged Conference,

April 30-May 2, 2008, Key Biscayne, Florida

-- Deutsche Bank 33rd Annual Health Care Conference, May 5-7, 2008,

Boston, Massachusetts

-- Bank of America 2008 Health Care Conference, May 13-15, 2008, Las

Vegas, Nevada

-- Rodman & Renshaw 5th Annual Global Healthcare Conference, May 19-20,

2008, Monte Carlo, Monaco

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the significance of 2007 events and activities; expected 2008 events and activities; upcoming milestones, including the timing of the month-12 ESMB review of lorcaserin, and the importance of such milestones; the protocol, des
'/>"/>